Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome

9 de junio de 2026 actualizado por: Song Yuanlin, Shanghai Zhongshan Hospital

This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.

The trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.

All subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

24

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yi Wei
  • Número de teléfono: +86 18872984075
  • Correo electrónico: yiwei4075@163.com

Ubicaciones de estudio

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200000
        • Reclutamiento
        • ShanghaiZhongshan
        • Contacto:
          • Yi Wei
          • Número de teléfono: +86 18872984075
          • Correo electrónico: yiwei4075@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Aged ≥18 years and <80 years, male or female.
  2. Definite diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition.
  3. Patients with PaO₂/FiO₂ < 200 mmHg and receiving invasive mechanical ventilation via endotracheal intubation.
  4. Diagnosis of ARDS confirmed no more than 72 hours prior to enrollment.
  5. No plan for parenthood within 1 year and agree to take effective contraceptive measures during the study period. Female participants of childbearing potential must have a negative serum pregnancy test.
  6. The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the investigational drug. The subject voluntarily signs the informed consent form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.

    -

Exclusion Criteria:

  1. Use of inhaled pulmonary vasodilators (e.g., nitric oxide or prostaglandins).
  2. Current receipt or planned receipt of extracorporeal membrane oxygenation (ECMO) during the study period.
  3. Expected survival < 3 months due to causes other than respiratory failure.
  4. Cerebrovascular or cardiovascular events within 3 months prior to study drug administration, including unstable angina, congestive heart failure, myocardial infarction within the past 12 months, hemodynamic instability, known left ventricular ejection fraction (LVEF) < 40%, or clinically significant arrhythmia or conduction abnormality.
  5. Inability to tolerate single-use bronchoscopic imaging catheter examination, including but not limited to the following: active massive hemoptysis; severe hypertension and arrhythmia; myocardial infarction or unstable angina within 4-6 weeks prior to screening; severe cardiac dysfunction; uncorrectable bleeding tendency (platelet count < 60 × 10⁹/L), such as severe coagulation disorders, uremia, or severe pulmonary hypertension; severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae.
  6. History of severe allergic reaction, or known allergy or hypersensitivity to any component of the investigational product.
  7. Breastfeeding or pregnant women.
  8. Participation in any drug clinical trial within 3 months prior to enrollment.
  9. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: 5 mg rhKGF-2
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
Sin intervención: Blank Control for 5 mg Cohort
Experimental: 10 mg rhKGF-2
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
Sin intervención: Blank Control for 10 mg Cohort
Experimental: 15 mg rhKGF-2
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
Sin intervención: Blank Control for 15 mg Cohort

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of adverse events (AE) and incidence of adverse drug reactions (ADR);
Periodo de tiempo: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Incidence of serious adverse events (SAE)
Periodo de tiempo: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Various laboratory test parameters:White blood cell (WBC) count
Periodo de tiempo: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Unit of measure: 3.5 - 9.5 × 10^9/L
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Various Laboratory test parameters: Serum creatinine (Cr) level
Periodo de tiempo: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Unit of measure: 44 -115 μmol/L
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Various laboratory test parameters: Total Bilirubin
Periodo de tiempo: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Unit of measure: 3.4-20.4 umol /L
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Incidence of airway spasm (increased airway resistance) caused by local drug stimulation
Periodo de tiempo: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Improvement rate of oxygenation indexPaO₂/FiO₂ ratio (PFR)
Periodo de tiempo: at Day 3 and Day 7
at Day 3 and Day 7
PaO₂/FiO₂ ratio (PFR) and its change from baseline
Periodo de tiempo: at Day 3, Day 5, and Day 7
at Day 3, Day 5, and Day 7
Number of days from baseline to first PaO₂/FiO₂ ratio (PFR) > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
Periodo de tiempo: From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
Change from baseline in the Murray Lung Injury Score(LIS).
Periodo de tiempo: at Day 7
Score (scale range: 0-4; higher scores indicate more severe lung injury)
at Day 7
Change from baseline in Radiographic Assessment of Lung Edema (RALE) score;
Periodo de tiempo: at Day 3, Day 7, Day 14, and Day 28
Score (scale range: 0-48; higher scores indicate a worse outcome);
at Day 3, Day 7, Day 14, and Day 28
Proportion of patients with improvement in ARDS severity grade
Periodo de tiempo: at Day 7 and Day 14
at Day 7 and Day 14
Proportion of patients with progression in ARDS severity grade
Periodo de tiempo: at Day 7 and Day 14
at Day 7 and Day 14
All-cause mortality
Periodo de tiempo: at Day 28
at Day 28
Systemic evaluation measures: Ventilator-free days at Day 28
Periodo de tiempo: at Day 28
Ventilator-free days at Day 28 (unit: days; higher scores indicate a better outcome).
at Day 28
Systemic evaluation measures: Non-ICU hospital stay days at Day 28
Periodo de tiempo: at Day 28.
Non-ICU hospital stay days at Day 28 (unit: days; higher scores indicate a better outcome as applicable).
at Day 28.
Systemic evaluation measures: Non-hospitalization days at Day 28
Periodo de tiempo: at Day 28
Non-hospitalization days at Day 28 (unit: days; higher scores indicate a better outcome).
at Day 28

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Yuanlin Song, Shanghai Zhongshan Hospital
  • Investigador principal: Jing Bi, Shanghai Zhongshan Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de mayo de 2026

Finalización primaria (Estimado)

30 de noviembre de 2026

Finalización del estudio (Estimado)

30 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

12 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de abril de 2026

Publicado por primera vez (Actual)

30 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de junio de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All IPD that underlie results in a publication.

Marco de tiempo para compartir IPD

Sharing will begin within 6 months after article publication.

Criterios de acceso compartido de IPD

IPD and supporting information will be avaible to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).

Tipo de información de apoyo para compartir IPD

  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir